Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$55.47 USD

55.47
3,077,855

-0.07 (-0.13%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Roche (RHHBY), AbbVie's Leukemia Drug Venclexta Get Full FDA Nod

Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).

Sheraz Mian headshot

Top Stock Reports for Amazon, Home Depot & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), The Home Depot (HD) and Sanofi (SNY).

Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage

Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates

J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.

Sanofi's Dupixent Meets All Goals in Asthma Study for Children

Sanofi's (SNY) blockbuster drug Dupixent meets primary as well as all key secondary goals in a late-stage study for treating moderate-to-severe asthma in children aged six-11 years.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs

Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.

The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia

The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia

Kinjel Shah headshot

Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia

After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.

Sanofi's MAA for Pompe Disease Candidate Gets EMA's Acceptance

The European Medicines Agency accepts for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa as a long-term enzyme replacement therapy for treating Pompe disease.

Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data

Alnylam (ALNY) releases positive top-line data from the ILLUMINATE-B pediatric phase III study of lumasiran, in development for the treatment of PH1.

Glaxo Gets FDA Nod for Nucala for Hypereosinophilic Syndrome

Glaxo's (GSK) Nucala becomes the first and only targeted biologic treatment to be approved for hypereosinophilic syndrome (HES), a rare disease caused by eosinophilic inflammation.

The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK

The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates

J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.

Sanofi/Glaxo to Supply 70M Coronavirus Vaccine Doses in Canada

Sanofi's (SNY) recombinant protein-based technology is being combined with Glaxo's pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion

Eli Lilly's (LLY) label expansion application for Olumiant to include atopic dermatitis in Europe patients gets CHMP recommendation for approval in Europe.

Ritujay Ghosh headshot

Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch

Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.

Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU

Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals

AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.

SNY vs. NVO: Which Stock Should Value Investors Buy Now?

SNY vs. NVO: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health

The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health

Sheraz Mian headshot

Top Analyst Reports for Walmart, Oracle & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Oracle (ORCL) and Sanofi (SNY).

Sanofi's Dupixent Gets Breakthrough Status for New Indication

Sanofi's (SNY) blockbuster drug, Dupixent gets Breakthrough Therapy designation from the FDA as potential treatment for eosinophilic esophagitis.

Has Sanofi (SNY) Outpaced Other Medical Stocks This Year?

Is (SNY) Outperforming Other Medical Stocks This Year?

Rajani Lohia headshot

7 Solid Low Price-to-Sales Picks With Room for Growth

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN

The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN